Edition:
India

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

8.75USD
23 Jan 2018
Change (% chg)

$0.44 (+5.29%)
Prev Close
$8.31
Open
$8.55
Day's High
$9.12
Day's Low
$8.46
Volume
101,007
Avg. Vol
38,166
52-wk High
$10.80
52-wk Low
$5.45

Latest Key Developments (Source: Significant Developments)

Chemocentryx reports Q3 revenue $9.0 million
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Chemocentryx Inc ::Chemocentryx reports third quarter 2017 financial results and recent highlights.Q3 revenue $9.0 million versus I/B/E/S view $9 million.Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​.Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​.Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​.Chemocentryx Inc - qtrly loss per share $0.13​.  Full Article

ChemoCentryx reports initial results from ongoing phase IB clinical trial of CCX872
Friday, 2 Sep 2016 

ChemoCentryx Inc : Reports initial results from ongoing phase IB clinical trial of CCX872 in patients with advanced pancreatic cancer . Expects to report progression-free survival (PFS) by end of 2016 . CCX872 was well tolerated by advanced pancreatic cancer patients. .Incidence and rate of adverse events were consistent with data reported historically for Folfirinox alone.  Full Article

Chemocentryx reports Q2 revenue of $2.8 million
Tuesday, 9 Aug 2016 

Chemocentryx Inc :Chemocentryx Inc says revenue was $2.8 million for three months ended june 30, 2016 compared to zero in same period in 2015.  Full Article

Chemocentryx receives priority medicines designation from EMA for CCX168
Wednesday, 1 Jun 2016 

Chemocentryx Inc :Chemocentryx Inc says received priority medicines designation from EMA for CCX168 for treatment of anca-associated vasculitis.  Full Article

Chemocentryx reports Q2 loss of $0.28 per share
Tuesday, 10 May 2016 

Chemocentryx Inc Full Article